Livogiva®
ACTIVE PRINCIPLE:
teriparatide
INDICATION:
Osteoporosis
DATE:
20/10/2020
STATUS:
Authorized
Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE:
teriparatide
INDICATION:
Osteoporosis
DATE:
20/10/2020
STATUS:
Authorized
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.